Abstract:Background Recent evidence indicates that inhibition of histone deacetylase (HDAC) protects the heart against myocardial injury and stimulates endogenous angiomyogenesis. However, it remains unknown whether HDAC inhibition produces the protective effect in the diabetic heart. We sought to determine whether HDAC inhibition preserves cardiac performance and suppresses cardiac remodeling in diabetic cardiomyopathy. Methods Adult ICR mice received an intraperitoneal injection of either streptozotocin (STZ, 200 mg/kg) to establish the diabetic model or vehicle to serve as control. Once hyperglycemia was confirmed, diabetic mice received sodium butyrate (1%), a specific HDAC inhibitor, in drinking water on a daily basis to inhibit HDAC activity. Mice were randomly divided into following groups, which includes Control , Control + Sodium butyrate ( NaBu ) , STZ and STZ + Sodium butyrate ( NaBu ), respectively. Myocardial function was serially assessed at 7, 14, 21 weeks following treatments. Results Echocardiography demonstrated that cardiac function was depressed in diabetic mice, but HDAC inhibition resulted in a significant functional improvement in STZ-injected mice. Likewise, HDAC inhibition attenuates cardiac hypertrophy, as evidenced by a reduced heart/tibia ratio and areas of cardiomyocytes, which is associated with reduced interstitial fibrosis and decreases in active caspase-3 and apoptotic stainings, but also increased angiogenesis in diabetic myocardium. Notably, glucose transporters (GLUT) 1 and 4 were up-regulated following HDAC inhibition, which was accompanied with increases of GLUT1 acetylation and p38 phosphorylation. Furthermore, myocardial superoxide dismutase, an important antioxidant, was elevated following HDAC inhibition in the diabetic mice. Conclusion HDAC inhibition plays a critical role in improving cardiac function and suppressing myocardial remodeling in diabetic heart.

Roles of histone deacetylase inhibitors in treatment of diabetes mellitus

Histone Deacetylases and Their Inhibitors: Molecular Mechanisms and Therapeutic Implications in Diabetes Mellitus

Histone deacetylases and inhibitors in diabetes mellitus and its complications

Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues

Improving Insulin Sensitivity with HDAC Inhibitor.

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Strategies in Developing Promising Histone Deacetylase Inhibitors.

Novel histone post-translational modifications in diabetes and complications of diabetes: The underlying mechanisms and implications

Advances of histone deacetylases inhibitors as novel anti-cancer agents in clinical study

The role of histone acetylation in diabetes mellitus

Progress in clinical study of histone deacetylases inhibitors as anticancer agents

HDAC11, an Emerging Therapeutic Target for Metabolic Disorders

Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats

An Update On The Emerging Approaches For Histone Deacetylase (Hdac) Inhibitor Drug Discovery And Future Perspectives

Advances in the Application of Histone Deacetylase Inhibitors in Eye Disease

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives

HDACi: molecular mechanisms and therapeutic implications in the innate immune system

Treatment of chronic kidney diseases with histone deacetylase inhibitors.

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy

Histone Deacetylase (HDAC) Inhibition Improves Myocardial Function and Prevents Cardiac Remodeling in Diabetic Mice